GeneBlocs are powerful tools to study and delineate signal transduction processes that regulate cell growth and transformation

被引:25
作者
Sternberger, M
Schmiedeknecht, A
Kretschmer, A
Gebhardt, F
Leenders, F
Czauderna, F
Von Carlowitz, I
Engle, M
Giese, K
Beigelman, L
Klippel, A
机构
[1] Atugen AG, D-13125 Berlin, Germany
[2] Atugen AG, Boulder, CO 80301 USA
[3] Ribzyme Pharmaceut Inc, Boulder, CO 80301 USA
来源
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT | 2002年 / 12卷 / 03期
关键词
D O I
10.1089/108729002760220734
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The study of signal transduction processes using antisense oligonucleotides is often complicated by low intracellular stability of the antisense reagents or by nonspecific effects that cause toxicity. Here, we introduce a new class of antisense molecules, so-called GeneBlocs, which are characterized by improved stability, high target RNA specificity, and low toxicity. GeneBlocs allow for efficient downregulation of mRNA expression at nanomolar concentrations, and they do not interfere with cell proliferation. We demonstrate these beneficial properties using a positive readout system. GeneBloc-mediated inhibition of tumor suppressor PTEN (phosphatase and tension homologue detected on chromosome 10) expression leads to hyperactivation of the phosphatidylinositol (PI) 3-kinase pathway, thereby mimicking the loss of PTEN function and its early consequences observed in mammalian cancer cells. Specifically, cells treated with PTEN GeneBlocs show functional activation of Akt, a downstream effector of PI 3-kinase signaling, and exhibit enhanced proliferation when seeded on a basement membrane matrix. In addition, GeneBlocs targeting the catalytic subunit of PI 3-kinase, p110, specifically inhibit signal transduction of endogenous or recombinant PI 3-kinase. This demonstrates that GeneBlocs are powerful tools to analyze and to modulate signal transduction processes and, therefore, represent alternative reagents for the validation of gene function.
引用
收藏
页码:131 / 143
页数:13
相关论文
共 43 条
[1]   Antisense therapeutics [J].
Agrawal, S ;
Zhao, QY .
CURRENT OPINION IN CHEMICAL BIOLOGY, 1998, 2 (04) :519-528
[2]   Mixed backbone oligonucleotides: Improvement in oligonucleotide-induced toxicity in vivo [J].
Agrawal, S ;
Zhao, Q .
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 1998, 8 (02) :135-139
[3]   Gatekeeper for endometrium: the PTEN tumor suppressor gene [J].
Ali, IU .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (11) :861-863
[4]   HETEROTRANSPLANTATION STUDIES WITH TISSUE-CULTURE CELL-LINES IN VARIOUS ANIMAL AND INVITRO HOST SYSTEMS [J].
BATHER, R ;
BECKER, BC ;
CONTRERAS, G ;
FURESZ, J .
JOURNAL OF BIOLOGICAL STANDARDIZATION, 1985, 13 (01) :13-22
[5]   CHEMICAL MODIFICATION OF HAMMERHEAD RIBOZYMES - CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE [J].
BEIGELMAN, L ;
MCSWIGGEN, JA ;
DRAPER, KG ;
GONZALEZ, C ;
JENSEN, K ;
KARPEISKY, AM ;
MODAK, AS ;
MATULICADAMIC, J ;
DIRENZO, AB ;
HAEBERLI, P ;
SWEEDLER, D ;
TRACZ, D ;
GRIMM, S ;
WINCOTT, FE ;
THACKRAY, VG ;
USMAN, N .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (43) :25702-25708
[6]   Antisense oligonucleotides: Is the glass half full or half empty? [J].
Bennett, CF .
BIOCHEMICAL PHARMACOLOGY, 1998, 55 (01) :9-19
[7]   DESIGN AND APPLICATION OF ANTISENSE OLIGONUCLEOTIDES IN CELL-CULTURE, IN-VIVO, AND AS THERAPEUTIC AGENTS [J].
BRYSCH, W ;
SCHLINGENSIEPEN, KH .
CELLULAR AND MOLECULAR NEUROBIOLOGY, 1994, 14 (05) :557-568
[8]   New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase AKT pathway [J].
Cantley, LC ;
Neel, BG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4240-4245
[9]   RATE OF DEGRADATION OF [ALPHA]-OLIGODEOXYNUCLEOTIDES AND [BETA]-OLIGODEOXYNUCLEOTIDES IN XENOPUS OOCYTES - IMPLICATIONS FOR ANTI-MESSENGER STRATEGIES [J].
CAZENAVE, C ;
CHEVRIER, M ;
THUONG, NT ;
HELENE, C .
NUCLEIC ACIDS RESEARCH, 1987, 15 (24) :10507-10521
[10]  
Coffer PJ, 1998, BIOCHEM J, V335, P1